Home
Resources
Publications
Amarogentin, a Secoiridoid Glycoside, Abrogates Platelet Activation Through PLC γ 2-PKC and MAPK Pathways

Amarogentin, a Secoiridoid Glycoside, Abrogates Platelet Activation Through PLC γ 2-PKC and MAPK Pathways

Ting-Lin Yen, Wan-Jung Lu, Li-Ming Lien, Philip Aloysius Thomas, Tzu-Yin Lee, Hou-Chang Chiu, Joen-Rong Sheu, Kuan-Hung Lin

Biomed Res Int. 2014;2014:728019.

PMID: 24868545

Abstract:

Amarogentin, an active principle of Gentiana lutea, possess antitumorigenic, antidiabetic, and antioxidative properties. Activation of platelets is associated with intravascular thrombosis and cardiovascular diseases. The present study examined the effects of amarogentin on platelet activation. Amarogentin treatment (15~60 μM) inhibited platelet aggregation induced by collagen, but not thrombin, arachidonic acid, and U46619. Amarogentin inhibited collagen-induced phosphorylation of phospholipase C (PLC) γ2, protein kinase C (PKC), and mitogen-activated protein kinases (MAPKs). It also inhibits in vivo thrombus formation in mice. In addition, neither the guanylate cyclase inhibitor ODQ nor the adenylate cyclase inhibitor SQ22536 affected the amarogentin-mediated inhibition of platelet aggregation, which suggests that amarogentin does not regulate the levels of cyclic AMP and cyclic GMP. In conclusion, amarogentin prevents platelet activation through the inhibition of PLC γ2-PKC cascade and MAPK pathway. Our findings suggest that amarogentin may offer therapeutic potential for preventing or treating thromboembolic disorders.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
AP21018848	Amarogentin		21018-84-8	Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: